Upstream Bio (NASDAQ:UPB) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Upstream Bio (NASDAQ:UPB) was given a new $51.00 price target on by analysts at Mizuho.
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study [Seeking Alpha]
Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.
Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge [Yahoo! Finance]